Biology of Gastrointestinal Stromal Tumors

KIT Mutations and Beyond

Anette Duensing, Michael Heinrich, Christopher D M Fletcher, Jonathan A. Fletcher

    Research output: Contribution to journalArticle

    54 Citations (Scopus)

    Abstract

    Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the digestive tract. Aspects of the morphology and immunophenotype in GISTs resemble those in the interstitial cells of Cajal (ICC), which are a specialized cell type responsible for coordinating peristaltic activity throughout the gastrointestinal tract. Therefore, it is possible that GISTs result from transformation of nonneoplastic progenitor cells that would normally differentiate towards an ICC endpoint. Activation of the KIT receptor tyrosine kinase is required for differentiation and proliferation of nonneoplastic ICC, and oncogenic KIT mutations are a crucial event in the development of most GISTs. These mutations can involve either the extracellular or intracellular domains of the KIT receptor, giving rise to conformational changes that enable constitutive, ligand-independent, activation of the KIT protein. Oncogenic KIT activation leads to phosphorylation of various substrate proteins and, in turn, to activation of signal transduction cascades regulating cell proliferation, apoptosis, chemotaxis, and adhesion. Recently, a small molecule tyrosine kinase inhibitor (STI571, imatinib mesylate, Gleevec®) directed against the enzymatic (kinase) domain of the KIT protein was found to produce dramatic clinical responses as monotherapy for metastatic GISTs. This review focuses on the biological and molecular genetic principles of GISTs, and particularly the role of mutant KIT as a therapeutic target.

    Original languageEnglish (US)
    Pages (from-to)106-116
    Number of pages11
    JournalCancer Investigation
    Volume22
    Issue number1
    DOIs
    StatePublished - 2004

    Fingerprint

    Gastrointestinal Stromal Tumors
    Interstitial Cells of Cajal
    Mutation
    Gastrointestinal Tract
    Receptor Protein-Tyrosine Kinases
    Chemotaxis
    Protein-Tyrosine Kinases
    Molecular Biology
    Signal Transduction
    Proteins
    Phosphotransferases
    Stem Cells
    Phosphorylation
    Cell Proliferation
    Apoptosis
    Ligands
    Imatinib Mesylate
    Neoplasms

    Keywords

    • GIST
    • Imatinib
    • KIT
    • Receptor tyrosine kinase
    • Sarcoma

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology

    Cite this

    Biology of Gastrointestinal Stromal Tumors : KIT Mutations and Beyond. / Duensing, Anette; Heinrich, Michael; Fletcher, Christopher D M; Fletcher, Jonathan A.

    In: Cancer Investigation, Vol. 22, No. 1, 2004, p. 106-116.

    Research output: Contribution to journalArticle

    Duensing, Anette ; Heinrich, Michael ; Fletcher, Christopher D M ; Fletcher, Jonathan A. / Biology of Gastrointestinal Stromal Tumors : KIT Mutations and Beyond. In: Cancer Investigation. 2004 ; Vol. 22, No. 1. pp. 106-116.
    @article{9c4fd2dd1d3c41e6a02223ad6da46f09,
    title = "Biology of Gastrointestinal Stromal Tumors: KIT Mutations and Beyond",
    abstract = "Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the digestive tract. Aspects of the morphology and immunophenotype in GISTs resemble those in the interstitial cells of Cajal (ICC), which are a specialized cell type responsible for coordinating peristaltic activity throughout the gastrointestinal tract. Therefore, it is possible that GISTs result from transformation of nonneoplastic progenitor cells that would normally differentiate towards an ICC endpoint. Activation of the KIT receptor tyrosine kinase is required for differentiation and proliferation of nonneoplastic ICC, and oncogenic KIT mutations are a crucial event in the development of most GISTs. These mutations can involve either the extracellular or intracellular domains of the KIT receptor, giving rise to conformational changes that enable constitutive, ligand-independent, activation of the KIT protein. Oncogenic KIT activation leads to phosphorylation of various substrate proteins and, in turn, to activation of signal transduction cascades regulating cell proliferation, apoptosis, chemotaxis, and adhesion. Recently, a small molecule tyrosine kinase inhibitor (STI571, imatinib mesylate, Gleevec{\circledR}) directed against the enzymatic (kinase) domain of the KIT protein was found to produce dramatic clinical responses as monotherapy for metastatic GISTs. This review focuses on the biological and molecular genetic principles of GISTs, and particularly the role of mutant KIT as a therapeutic target.",
    keywords = "GIST, Imatinib, KIT, Receptor tyrosine kinase, Sarcoma",
    author = "Anette Duensing and Michael Heinrich and Fletcher, {Christopher D M} and Fletcher, {Jonathan A.}",
    year = "2004",
    doi = "10.1081/CNV-120027585",
    language = "English (US)",
    volume = "22",
    pages = "106--116",
    journal = "Cancer Investigation",
    issn = "0735-7907",
    publisher = "Informa Healthcare",
    number = "1",

    }

    TY - JOUR

    T1 - Biology of Gastrointestinal Stromal Tumors

    T2 - KIT Mutations and Beyond

    AU - Duensing, Anette

    AU - Heinrich, Michael

    AU - Fletcher, Christopher D M

    AU - Fletcher, Jonathan A.

    PY - 2004

    Y1 - 2004

    N2 - Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the digestive tract. Aspects of the morphology and immunophenotype in GISTs resemble those in the interstitial cells of Cajal (ICC), which are a specialized cell type responsible for coordinating peristaltic activity throughout the gastrointestinal tract. Therefore, it is possible that GISTs result from transformation of nonneoplastic progenitor cells that would normally differentiate towards an ICC endpoint. Activation of the KIT receptor tyrosine kinase is required for differentiation and proliferation of nonneoplastic ICC, and oncogenic KIT mutations are a crucial event in the development of most GISTs. These mutations can involve either the extracellular or intracellular domains of the KIT receptor, giving rise to conformational changes that enable constitutive, ligand-independent, activation of the KIT protein. Oncogenic KIT activation leads to phosphorylation of various substrate proteins and, in turn, to activation of signal transduction cascades regulating cell proliferation, apoptosis, chemotaxis, and adhesion. Recently, a small molecule tyrosine kinase inhibitor (STI571, imatinib mesylate, Gleevec®) directed against the enzymatic (kinase) domain of the KIT protein was found to produce dramatic clinical responses as monotherapy for metastatic GISTs. This review focuses on the biological and molecular genetic principles of GISTs, and particularly the role of mutant KIT as a therapeutic target.

    AB - Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the digestive tract. Aspects of the morphology and immunophenotype in GISTs resemble those in the interstitial cells of Cajal (ICC), which are a specialized cell type responsible for coordinating peristaltic activity throughout the gastrointestinal tract. Therefore, it is possible that GISTs result from transformation of nonneoplastic progenitor cells that would normally differentiate towards an ICC endpoint. Activation of the KIT receptor tyrosine kinase is required for differentiation and proliferation of nonneoplastic ICC, and oncogenic KIT mutations are a crucial event in the development of most GISTs. These mutations can involve either the extracellular or intracellular domains of the KIT receptor, giving rise to conformational changes that enable constitutive, ligand-independent, activation of the KIT protein. Oncogenic KIT activation leads to phosphorylation of various substrate proteins and, in turn, to activation of signal transduction cascades regulating cell proliferation, apoptosis, chemotaxis, and adhesion. Recently, a small molecule tyrosine kinase inhibitor (STI571, imatinib mesylate, Gleevec®) directed against the enzymatic (kinase) domain of the KIT protein was found to produce dramatic clinical responses as monotherapy for metastatic GISTs. This review focuses on the biological and molecular genetic principles of GISTs, and particularly the role of mutant KIT as a therapeutic target.

    KW - GIST

    KW - Imatinib

    KW - KIT

    KW - Receptor tyrosine kinase

    KW - Sarcoma

    UR - http://www.scopus.com/inward/record.url?scp=1942473596&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=1942473596&partnerID=8YFLogxK

    U2 - 10.1081/CNV-120027585

    DO - 10.1081/CNV-120027585

    M3 - Article

    VL - 22

    SP - 106

    EP - 116

    JO - Cancer Investigation

    JF - Cancer Investigation

    SN - 0735-7907

    IS - 1

    ER -